Chemotherapy and cardiac toxicity - the lesser of two evils
Author: John Kenyon, CNA
Submitted: September 15, 2010. Updated: October 07, 2010.
Category: Cardiology | Family Medicine | Hematology | Internal Medicine | Medical Students | Preventive Medicine | Oncology | Pathology | Pharmacy | Radiology | Research
One of the most dreaded side effects of certain chemotherapy agents is their effect on the heart. The paradox comes from the fact that these drugs, while only a handful, are among the few chemotherapy agents with a substantial survival benefit. In…
Read more... (Comments: 0)
Massive Recall of Tylenol in USA, UAE and Fiji
Author: Tamer M. Fouad, M.D.
Submitted: January 16, 2010. Updated: January 16, 2010.
Category: Family Medicine | Internal Medicine | Neurology | Orthopedics | Pharmacy | Rheumatology | Surgery | Anesthesiology & Pain
Johnson and Johnson is extending the voluntary recall of certain lots of OTC products in the Americas, the United Arab Emirates (UAE), and Fiji. This includes Tylenol, Motrin and St. Joseph’s aspirin (FULL RECALLED PRODUCT LIST BELOW). The company…
Read more... (Comments: 0)
Rituximab drastically reduces efficacy of H1N1 vaccine in rheumatoid patients
Author: Tamer M. Fouad, M.D.
Submitted: January 07, 2010. Updated: January 07, 2010.
Category: Family Medicine | Infections | Internal Medicine | Immunology | Preventive Medicine | Oncology | Pharmacy | Pulmonology | Rheumatology
Rheumatoid arthritis (RA) patients are partially protected by the influenza vaccine 6-10 months after treatment with rituximab. Researchers determined that while the flu vaccine is safe, it is ineffective for RA patients in the first 6 months following…
Read more... (Comments: 0)
Four drug adjuvant chemotherapy with capecitabine improves breast cancer survival
Author: Tamer M. Fouad, M.D.
Submitted: January 03, 2010. Updated: January 03, 2010.
Category: Oncology | Pharmacy
Joensuu et al published an interesting study1 in which they randomized 1500 women with axillary node-positive or high-risk node-negative breast cancer, in an open-label trial, to either three cycles of capecitabine and docetaxel followed…
Read more... (Comments: 0)
